Harvard Bioscience 2025 revenue $86.6M, net loss $56.7M incl $48M goodwill impairment; permanent CFO appointed

HARVARD BIOSCIENCE INC

Q4 revenue $23.7M (down from $24.6M YoY); gross margin 59.7% (up from 57.1%).
Full-year net loss $56.7M driven by $48.0M goodwill impairment in Q1 2025.
Adjusted EBITDA $8.1M for FY2025 vs $7.2M in FY2024; operating cash flow $6.7M vs $1.4M.
Interim CFO Mark Frost appointed permanent CFO effective March 12, 2026.
Introduced FY2026 guidance for revenue growth from new translational science products; no specific figures provided.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HARVARD BIOSCIENCE INC reported financial results for three and twelve months ended December 31, 2025.

Period: three and twelve months ended December 31, 2025
Result: reported results

Exact text from the filing

On March 12, 2026, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the three and twelve months ended December 31, 2025, and the details of a related conference call to be held at 8:00 AM ET on March 12, 2026. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

HARVARD BIOSCIENCE INC filing history →

Source: SEC EDGAR

accession 0001171843-26-001504

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.